No annual revenue total was found in LANTERN PHARMA INC.'s SEC filings.
Lantern Pharma Inc. (LTRN) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$15.7 million. As of Jun 30, 2026 it held $7.4 million in cash and investments and $39,715 in total debt.
Revenue
—
Net income (TTM)
$-18.65M
+3.1% vs year-ago TTM
Operating cash flow (TTM)
$-14.08M
+21.2% vs year-ago TTM
Free cash flow
$-15.68M
+12.0% vs prior year
EPS (TTM)
$-1.63
+8.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
11.30M
+0.4% vs prior year
Net cash
$7.32M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LTRN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- TX
- Headquarters
- Dallas, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1763950
- Former names
- Lantern Pharma (until Jan 14, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$18.0M | -$22.2M | -$17.9M | -$14.4M | — |
| Net income | -$17.1M | -$20.8M | -$16.0M | -$14.3M | -$12.4M |
| Diluted EPS | -$1.57 | -$1.93 | -$1.47 | — | — |
| Operating cash flow | -$15.7M | -$17.8M | -$14.3M | -$12.8M | -$10.6M |
| Free cash flow | -$15.7M | -$17.8M | -$14.4M | -$12.8M | — |
| Total assets | $11.0M | $25.6M | $43.6M | $58.8M | $74.0M |
| Total liabilities | $4.5M | $4.4M | $2.7M | $2.8M | $2.4M |
| Stockholders' equity | $6.5M | $21.2M | $40.9M | $56.0M | $71.6M |
| Cash and investments | $10.1M | $24.0M | $41.3M | $55.2M | $70.7M |
| Total debt | $78,539 | $243,657 | $234,471 | $52,890 | $204,948 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Oct 21, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Listing notice
|
Oct 1, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 30, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 24, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 14, 2026 | Aug 14, 2026 |
All 262 Lantern Pharma Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.